Here's What We're Looking For From Health Advance Inc (OTCMKTS:HADV)

Health Advance Inc (OTCMKTS:HADV) has been one of the most actively traded OTC stocks over the past month or so, but nobody really knows why. At least, that is, not officially. The company rose to highs north of $4 a share mid November, driven by the announcement that the company is set too acquire private UK corporation Hantian Labs. A couple of days' post-highs, however, Health Advance collapsed to $0.18 – a more than 95% decline – on much higher than standard volume. No fresh news hit press, and the company itself has since put out a release stating that it knows of no reason for the unusual trading volume, and that there is no significant information to disclose.Chances are, the move came as traders booked profits on what had been an extremely strong ten week run. The company gained close to 8,000% from late September to the above mentioned highs, and it had to correct at some point. That it would correct so dramatically isn’t too much of a surprise, either. The acquisition efforts aside, Health Advance is essentially a shell. It doesn’t generate any revenues, and its balance sheet is practically empty.The question now, is whether there's an opportunity to get in here ahead of a return to the upside momentum. If the Hantian acquisition goes through, there just might be. With a few catalysts slated for the next month or so, there's just enough of a news flow potential to get the stock moving again, and we think that if this one starts moving, there's plenty of speculative volume ready to pull the trigger on a momentum play.Here's what we're looking for.We've said that the company put out a release saying it didn’t know why volume was unusual, but alongside this announcement, it also gave us a bit of insight into potential time frames for some key events.First, Health Advance was scheduled to put out its latest 10-K before October 31, 2016. The release would have detailed financials and operations for the twelve months to July 31, but the company failed to do so, and instead put out an NT addressing the delay. Well, we say addressing, but it didn’t really offer up any information as to the nature of the delay. The report was supposed to hit on or before November 15, but again, this didn’t happen. In the latest release, management suggested that the report will hit the SEC, and to quote the release, within the next two weeks. This was on November 21, so we’ve got at most a few days before the company files.This is our first catalyst. We're not expecting much, but it will at least offer some insight into operations, and with any luck the company will focus on Hantian in an accompanying business update. Clarity should translate to trigger pulling, and trigger pulling should translate to some upside momentum.Second, and this is the big one, is the Hantian closing. Again in the volume related release, management stated that it expects to close the Hantian deal within the next 3-4 weeks. Lining this frame up with the November 21 release date, that takes us to somewhere around the second week of December. When this deal closes (assuming it does) it essentially represents the shifting of Health Advance from a no cash, no sales company to one with quantifiable assets and sales potential. As such, a close would necessitate a complete revaluation, and at its current price, we think the only logical revaluation is to the upside.Of course, the risk is that the deal never closes, and that for whatever reason, Health Advance fails to get its 10-K out this week. In either of these two events, there's probably some more downside pressure near term.Now we wait and see what move the company makes.We will be updating our subscribers as soon as we know more. For the latest updates on HADV, sign up below!Disclosure: We have no position in HADV and have not been compensated for this article.